Cytrx highlights immunitybio's use of aldoxorubicin in ongoing clinical studies for various forms of cancer

Los angeles--(business wire)--cytrx corporation (otcqb:cytr) (“cytrx” or the “company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today highlighted immunitybio, inc.'s (nasdaq: ibrx) ("immunitybio") recent clinical developments in the study of aldoxorubicin to treat various cancers. cytrx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to immunitybio in 2017. the company
IBRX Ratings Summary
IBRX Quant Ranking